Contrast agents for applications including perfusion imaging
View Patent ↗The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-I, and an imaging moiety, and scanning the subject using diagnostic imaging.
1. A method of imaging at least a portion of the central nervous system (CNS) in a subject, comprising:
administering to the subject a contrast agent having a structure as in Formula (II),
wherein:
J is selected from N(R 27 ), S, O, C(═O), C(═O)O, NHCH 2 CH 2 O, a bond, or C(═O)N(R 27 );
K and L, when present, are independently selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, alkyl, heteroaryl, and an imaging moiety, each of which is optionally substituted;
M is selected from alkoxyalkyl or alkyloxy, each of which is optionally substituted, or
L and M, together with the atom to which they are attached, form a ring, optionally substituted;
Q is halo or haloalkyl;
n is 0, 1, 2, or 3;
R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , and R 27 are independently selected from hydrogen, alkyl, optionally substituted, and an imaging moiety;
R 29 is alkyl, optionally substituted; and
Y is carbon or oxygen; provided that when Y is oxygen, K and L are absent and M is alkoxyalkyl, optionally substituted,
wherein at least one imaging moiety is present in Formula (II); and
scanning the subject using diagnostic imaging to produce an image of at least a portion of the CNS.
2. The method as in claim 1 , wherein the method of imaging at least a portion of the CNS in the subject comprises imaging perfusion in the brain of the subject.
3. A method as in claim 1 , wherein the image is used in the diagnosis of a subject.
4. A method as in claim 3 , wherein the diagnosis is a diagnosis of a CNS disorder or condition.
5. A method as in claim 1 , wherein the image is used to determine the stage of a disease.
6. A method as in claim 5 , wherein the disease is a CNS disorder or condition.
7. A method as in claim 1 , further comprising selecting a treatment for a central nervous system (CNS) disorder or condition in the subject based at least in part on the image of at least a portion of the CNS of the subject.
8. A method as in claim 1 , further comprising evaluating a treatment of a central nervous system (CNS) disorder or condition in the subject based at least in part on the image of at least a portion of the CNS of the subject.
9. A method as in claim 2 , further comprising selecting a treatment of a central nervous system (CNS) disorder or condition in the subject based at least in part on the image of at least a portion of the brain.
10. A method as in claim 2 , further comprising evaluating a treatment of a central nervous system (CNS) disorder or condition in the subject based at least in part on the image of at least a portion of the brain.
11. A method as in claim 1 , wherein J is O, Q is Cl, and R 29 is C 1 -C 6 alkyl.
12. A method as in claim 1 , wherein each of K and L is hydrogen, Y is carbon, and M is alkoxyalkyl or alkyloxy, optionally substituted with an imaging moiety.
13. A method as in claim 1 , wherein the imaging moiety is 18 F.
14. A method as in claim 1 , wherein M is alkoxyalkyl or alkyloxy substituted with an imaging moiety.
15. A method as in claim 1 , wherein the contrast agent is: